Exploring a role for heteromerization in GPCR signalling specificity
- PMID:21158738
- PMCID: PMC3115900
- DOI: 10.1042/BJ20100458
Exploring a role for heteromerization in GPCR signalling specificity
Abstract
The critical involvement of GPCRs (G-protein-coupled receptors) in nearly all physiological processes, and the presence of these receptors at the interface between the extracellular and the intracellular milieu, has positioned these receptors as pivotal therapeutic targets. Although a large number of drugs targeting GPCRs are currently available, significant efforts have been directed towards understanding receptor properties, with the goal of identifying and designing improved receptor ligands. Recent advances in GPCR pharmacology have demonstrated that different ligands binding to the same receptor can activate discrete sets of downstream effectors, a phenomenon known as 'ligand-directed signal specificity', which is currently being explored for drug development due to its potential therapeutic advantage. Emerging studies suggest that GPCR responses can also be modulated by contextual factors, such as interactions with other GPCRs. Association between different GPCR types leads to the formation of complexes, or GPCR heteromers, with distinct and unique signalling properties. Some of these heteromers activate discrete sets of signalling effectors upon activation by the same ligand, a phenomenon termed 'heteromer-directed signalling specificity'. This has been shown to be involved in the physiological role of receptors and, in some cases, in disease-specific dysregulation of a receptor effect. Hence targeting GPCR heteromers constitutes an emerging strategy to select receptor-specific responses and is likely to be useful in achieving specific beneficial therapeutic effects.
Figures



Similar articles
- GPCR heteromers: An overview of their classification, function and physiological relevance.Dale NC, Johnstone EKM, Pfleger KDG.Dale NC, et al.Front Endocrinol (Lausanne). 2022 Aug 30;13:931573. doi: 10.3389/fendo.2022.931573. eCollection 2022.Front Endocrinol (Lausanne). 2022.PMID:36111299Free PMC article.Review.
- History and biological significance of GPCR heteromerization in the neuroendocrine system.Tadagaki K, Jockers R, Kamal M.Tadagaki K, et al.Neuroendocrinology. 2012;95(3):223-31. doi: 10.1159/000330000. Epub 2011 Dec 9.Neuroendocrinology. 2012.PMID:22156565Review.
- Heteromerization of G protein-coupled receptors: relevance to neurological disorders and neurotherapeutics.Albizu L, Moreno JL, González-Maeso J, Sealfon SC.Albizu L, et al.CNS Neurol Disord Drug Targets. 2010 Nov;9(5):636-50. doi: 10.2174/187152710793361586.CNS Neurol Disord Drug Targets. 2010.PMID:20632964Free PMC article.Review.
- Arrestin recruitment and signaling by G protein-coupled receptor heteromers.Mores KL, Cassell RJ, van Rijn RM.Mores KL, et al.Neuropharmacology. 2019 Jul 1;152:15-21. doi: 10.1016/j.neuropharm.2018.11.010. Epub 2018 Nov 9.Neuropharmacology. 2019.PMID:30419245Free PMC article.Review.
- GPCR homomers and heteromers: a better choice as targets for drug development than GPCR monomers?Casadó V, Cortés A, Mallol J, Pérez-Capote K, Ferré S, Lluis C, Franco R, Canela EI.Casadó V, et al.Pharmacol Ther. 2009 Nov;124(2):248-57. doi: 10.1016/j.pharmthera.2009.07.005. Epub 2009 Aug 5.Pharmacol Ther. 2009.PMID:19664655Free PMC article.Review.
Cited by
- Taking two to tango: a role for ghrelin receptor heterodimerization in stress and reward.Schellekens H, Dinan TG, Cryan JF.Schellekens H, et al.Front Neurosci. 2013 Aug 30;7:148. doi: 10.3389/fnins.2013.00148.Front Neurosci. 2013.PMID:24009547Free PMC article.Review.
- Adrenergic Agonists Bind to Adrenergic-Receptor-Like Regions of the Mu Opioid Receptor, Enhancing Morphine and Methionine-Enkephalin Binding: A New Approach to "Biased Opioids"?Root-Bernstein R, Turke M, Subhramanyam UKT, Churchill B, Labahn J.Root-Bernstein R, et al.Int J Mol Sci. 2018 Jan 17;19(1):272. doi: 10.3390/ijms19010272.Int J Mol Sci. 2018.PMID:29342106Free PMC article.
- Dopamine-galanin receptor heteromers modulate cholinergic neurotransmission in the rat ventral hippocampus.Moreno E, Vaz SH, Cai NS, Ferrada C, Quiroz C, Barodia SK, Kabbani N, Canela EI, McCormick PJ, Lluis C, Franco R, Ribeiro JA, Sebastião AM, Ferré S.Moreno E, et al.J Neurosci. 2011 May 18;31(20):7412-23. doi: 10.1523/JNEUROSCI.0191-11.2011.J Neurosci. 2011.PMID:21593325Free PMC article.
- Heterodimerization between the lutropin and follitropin receptors is associated with an attenuation of hormone-dependent signaling.Feng X, Zhang M, Guan R, Segaloff DL.Feng X, et al.Endocrinology. 2013 Oct;154(10):3925-30. doi: 10.1210/en.2013-1407. Epub 2013 Jul 3.Endocrinology. 2013.PMID:23825122Free PMC article.
- Heterodimerization with Its splice variant blocks the ghrelin receptor 1a in a non-signaling conformation: a study with a purified heterodimer assembled into lipid discs.Mary S, Fehrentz JA, Damian M, Gaibelet G, Orcel H, Verdié P, Mouillac B, Martinez J, Marie J, Banères JL.Mary S, et al.J Biol Chem. 2013 Aug 23;288(34):24656-65. doi: 10.1074/jbc.M113.453423. Epub 2013 Jul 9.J Biol Chem. 2013.PMID:23839942Free PMC article.
References
- Ma P, Zemmel R. Value of novelty? Nat. Rev. Drug Discovery. 2002;1:571–572. - PubMed
- Drews J. Genomic sciences and the medicine of tomorrow. Nat. Biotechnol. 1996;14:1516–1518. - PubMed
- Pierce KL, Premont RT, Lefkowitz RJ. Seven-transmembrane receptors. Nat. Rev. Mol. Cell Biol. 2002;3:639–650. - PubMed
- Urban JD, Clarke WP, von Zastrow M, Nichols DE, Kobilka B, Weinstein H, Javitch JA, Roth BL, Christopoulos A, Sexton PM, et al. Functional selectivity and classical concepts of quantitative pharmacology. J. Pharmacol. Exp. Ther. 2007;320:1–13. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- DA01952/DA/NIDA NIH HHS/United States
- P20 AA017067-04/AA/NIAAA NIH HHS/United States
- P20 AA017067/AA/NIAAA NIH HHS/United States
- R01 DA008863-17/DA/NIDA NIH HHS/United States
- R56 DA008863/DA/NIDA NIH HHS/United States
- GGP06166/TI_/Telethon/Italy
- P50 GM071558/GM/NIGMS NIH HHS/United States
- R37 DA008863/DA/NIDA NIH HHS/United States
- K05 DA019521-08/DA/NIDA NIH HHS/United States
- K05 DA019521/DA/NIDA NIH HHS/United States
- GM071558/GM/NIGMS NIH HHS/United States
- DA08863/DA/NIDA NIH HHS/United States
- R01 DA008863/DA/NIDA NIH HHS/United States
- P50 GM071558-05/GM/NIGMS NIH HHS/United States
- AA017067/AA/NIAAA NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources